Intercept Pharmaceuticals Statistics
Share Statistics
Intercept Pharmaceuticals has 41.83M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 41.83M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 584,432 |
| FTD / Avg. Volume | 28.45% |
Short Selling Information
The latest short interest is 10.14M, so 24.23% of the outstanding
shares have been sold short.
| Short Interest | 10.14M |
| Short % of Shares Out | 24.23% |
| Short % of Float | 25.18% |
| Short Ratio (days to cover) | 8.34 |
Valuation Ratios
The PE ratio is 3.63 and the forward
PE ratio is null.
Intercept Pharmaceuticals's PEG ratio is
-0.02.
| PE Ratio | 3.63 |
| Forward PE | n/a |
| PS Ratio | 1.46 |
| Forward PS | n/a |
| PB Ratio | 4.49 |
| P/FCF Ratio | -15.3 |
| PEG Ratio | -0.02 |
Financial Ratio HistoryEnterprise Valuation
Intercept Pharmaceuticals has an Enterprise Value (EV) of 700.53M.
| EV / Sales | 2.45 |
| EV / EBITDA | -11.35 |
| EV / EBIT | -26.16 |
| EV / FCF | -25.62 |
Financial Position
The company has a current ratio of 2.35,
with a Debt / Equity ratio of 3.57.
| Current Ratio | 2.35 |
| Quick Ratio | 2.32 |
| Debt / Equity | 3.57 |
| Debt / EBITDA | -5.39 |
| Debt / FCF | -12.16 |
| Interest Coverage | -3.19 |
Financial Efficiency
Return on Equity is 123.74% and Return on Invested Capital is 10.55%.
| Return on Equity | 123.74% |
| Return on Assets | 20.8% |
| Return on Invested Capital | 10.55% |
| Revenue Per Employee | $837,859.24 |
| Profits Per Employee | $337,753.67 |
| Employee Count | 341 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 0.15 |
Taxes
| Income Tax | -290.03M |
| Effective Tax Rate | 165.87% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 0.88, so Intercept Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.88 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 16.63 |
| 200-Day Moving Average | 14.75 |
| Relative Strength Index (RSI) | 75.79 |
| Average Volume (20 Days) | 2,054,565 |
Income Statement
In the last 12 months, Intercept Pharmaceuticals had revenue of 285.71M
and earned 115.17M
in profits. Earnings per share was 3.41.
| Revenue | 285.71M |
| Gross Profit | 284.73M |
| Operating Income | -68.22M |
| Net Income | 115.17M |
| EBITDA | -61.7M |
| EBIT | -153.47M |
| Earnings Per Share (EPS) | 3.41 |
Full Income StatementBalance Sheet
The company has 50.52M in cash and 332.67M in
debt, giving a net cash position of -282.16M.
| Cash & Cash Equivalents | 50.52M |
| Total Debt | 332.67M |
| Net Cash | -282.16M |
| Retained Earnings | -2.14B |
| Total Assets | 393.16M |
| Working Capital | 292.6M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -26.78M
and capital expenditures -568K, giving a free cash flow of -27.35M.
| Operating Cash Flow | -26.78M |
| Capital Expenditures | -568K |
| Free Cash Flow | -27.35M |
| FCF Per Share | -0.81 |
Full Cash Flow StatementMargins
Gross margin is 99.66%, with operating and profit margins of -23.88% and 40.31%.
| Gross Margin | 99.66% |
| Operating Margin | -23.88% |
| Pretax Margin | -61.2% |
| Profit Margin | 40.31% |
| EBITDA Margin | -21.59% |
| EBIT Margin | -23.88% |
| FCF Margin | -9.57% |
